What is a recurrence of chronic hepatitis B in the treatment process, the application of antiviral drugs (lamivudine, adefovir, entecavir, t
What is a recurrence of chronic hepatitis B in the treatment process, the application of antiviral drugs (lamivudine, adefovir, entecavir, telbivudine, Cave) when it reached the stopping condition (i.e. to HBeAg positive hepatitis B, liver function returned to normal, negative DNA) and withdrawal. After stopping the drug to continue to observe, found that some patients with DNA positive with or without liver dysfunction, called recurrence, need to continue antiviral therapy.
Two, what is the resistance in chronic hepatitis B in the treatment process, the use of antiviral drugs (lamivudine, adefovir, entecavir, telbivudine and so on), continuous medication process, first because of hepatitis B virus DNA positive after antiviral negative (usually 3 months), and continue to use the drugs, without stopping in the observation process, hepatitis B virus DNA positive, known as resistance (usually in the medication after one year).
Three, what is the primary and secondary resistance. Primary drug resistance: clinical medication from the beginning to three months, half a year to one year, individual patient medication, patients with hepatitis B virus DNA is always positive (in part by the high to low copy copy, but not always negative). Secondary resistance: antiviral treatment for 1 to 2 years, the first is DNA negative, continue to use DNA from negative to positive, the condition is called secondary resistance.
Four, how to reduce resistance. Clinical on chronic hepatitis B and cirrhosis patients need long time medication, in order to avoid the occurrence of drug resistance appear very quickly, generally use the combined use of drugs, such as lamivudine combined with adefovir.